Proposal of Standardization to Assess Adherence With Medication Records: Methodology Matters

Annals of Pharmacotherapy

Volumn 50, Issue 5, 2016, Pages 360-368

  Arnet, Isabelle ^a   Kooij, Marcel J ^b   Messerli, Markus ^a   Hersberger, Kurt E ^a   Heerdink, Eibert R ^b   Bouvy, Marcel ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

adherence; measurements; medication; operationalization; standards

Indexed keywords

ACCURACY; ARTICLE; CONSENSUS; MEDICATION COMPLIANCE; METHODOLOGY; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; STANDARD; STANDARDIZATION; CLASSIFICATION; DRUG MONITORING; ELECTRONIC HEALTH RECORD; HUMAN; PRESCRIPTION; STANDARDS;

DRUG MONITORING; DRUG PRESCRIPTIONS; ELECTRONIC HEALTH RECORDS; HUMANS; MEDICATION ADHERENCE;

EID: 84963865293     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016634106     Document Type: Article

References (38)

1. P.M.HoJ.S.RumsfeldF.A.Masoudi. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
2. J.N.RasmussenA.ChongD.A.AlterRelationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-186.
3. P.A.CaetanoJ.M.C.LamS.G.MorganToward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28:1411-1424, discussion 1410.
4. A.M.PetersonD.P.NauJ.A.Cramer. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3-12.
5. E.L.P.SattlerJ.S.LeeM.Perri. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30:383-399.
6. L.M.HessM.A.RaebelD.A.Conner. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-1288.
7. S.KarveM.A.ClevesM.Helm. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009;12:989-995.
8. T.WilkeA.GrothS.Mueller. How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus. Eur J Health Econ. 2013;14:551-568.
9. L.LaforestI.LicajG.Devouassoux. Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease. Chron Respir Dis. 2013;10:11-18.
10. C.L.BrysonD.H.AuB.Young. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care. 2007;45:497-504.
11. A.B.WilliamsK.R.AmicoC.Bova. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17:284-297.
12. B.VrijensS.De GeestD.A.Hughes. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705.
13. I.ArnetI.AbrahamM.Messerli. A method for calculating adherence to polypharmacy from dispensing data records. Int J Clin Pharm. 2013;36:192-201.
14. L.ScheenL.BrandtR.Bodén. Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder: a nationwide cohort study. J Affect Disord. 2015;172:204-210.
15. S.AndradeK.KahlerF.Frech. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574.
16. A.BalasubramanianM.A.BrookhartV.Goli. Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med. 2013;6:839-848.
17. R.A.GreevyM.M.HuizingaC.L.Roumie. Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling. Clin Pharmacol Ther. 2011;90:813-819.
18. C.KozmaA.ParisM.InghamQuality measures and adherence: potential hazards of using administrative claims to measures biologic specialty pharmaceutical immunology product adherence when days’ supply is unspecified (conference abstract, 15th Annual European Congress of Rheumatology, Jun 11-14, 2014). Ann Rheum Dis. 2014;73:339-340.
19. R.BalkrishnanD.B.ChristensenA comparison of medication adherence indices to assess long-term inhaled corticosteroid medication use. J Asthma. 2001;38:91-98.
20. J.F.SteinerA.V.ProchazkaThe assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
21. F.LeenenA.FourneyG.Notman. Persistence of anti-hypertensive effect after “missed doses” of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol. 1996;41:83-88.
22. H.C.J.GeersM.L.BouvyE.R.Heerdink. Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. Ann Pharmacother. 2011;45:576-581.
23. C.Holkmann OlsenA.MocroftO.Kirk. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8:96-104.
24. Z.FoxA.PhillipsC.Cohen. Viral re-suppression and detection of drug resistance following interruption of a suppressive NNRTI-based regimen. AIDS. 2008;22:2279-2289.
25. W.TinagoJ.A.O’HalloranR.M.O’Halloran. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions. HIV Med. 2014;15:224-232.
26. D.M.MooreW.ZhangB.Yip. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11:299-307.
27. M.BrookhartA.R.PatrickS.Schneeweiss. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847-852.
28. M.J.KorhonenA.Helin-SalmivaaraR.HuupponenDynamics of long-term statin therapy. Eur J Clin Pharmacol. 2011;67:925-931.
29. D.Nau. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf. Accessed September 29, 2015.
30. B.C.MartinE.K.Wiley-ExleyS.Richards. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43:36-44.
31. E.J.F.LambertsG.NijpelsL.M.C.Welschen. Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf. 2011;20:351-358.
32. A.ParienteA.Fourrier-ReglatF.Bazin. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012;78:957-963.
33. S.L.RogersM.R.FarlowR.S.Doody. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology. 1998;50:136-145.
34. P.DoroR.BenkoE.Kosik. Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol. 2005;61:893-897.
35. L.ScottCalculating medication compliance, adherence, and persistence in administrative pharmacy claims databases. Pharmaceutical Programming. 2008;1:13-19.
36. P.HarbigI.BaratP.Lund Nielsen. Instantaneous detection of nonadherence: quality, strength, and weakness of an electronic prescription database. Pharmacoepidemiol Drug Saf. 2012;21:323-328.
37. Department of Health and Human Services. Electronic prescribing incentive fact sheet: introduction to E-prescribing incentive. http://www.cms.gov/PQRI/Downloads/PQRIEPrescribingFactSheet.pdf. Accessed August 5, 2015.
38. S.B.JosephM.J.SowM.F.Furukawa. E-prescribing adoption and use increased substantially following the start of a federal incentive program. Health Aff (Millwood). 2013;32:1221-1227.